KAVI

0

Strategic partnerships between academia, industry and the government needed to unlock Kenya’s Biomanufacturing potential

Dr. Ouma Oluga, Ps, State Department for Medical Services, flanked by Dean FHS Prof. Daniel Ojuka, Dr. Wesley Ronoh the CEO of Kenya BioVax Institute, the Chairman of Kenya vision 2030 board, Dr. Emmnuel Nzai, institutional leaders, FHS faculty members and other stakeholders.

Stakeholders in the health sector have underscored the need for strategic collaboration within academia, industry and the government spheres of the sector in order to drive development and advance health in the country.

0

KAVI Institute of Clinical Research launches IAVI W001 study

The first volunteer enrolled in IAVI-W001 receives the study vaccine.

KAVI Institute of Clinical Research enrolled the first volunteer to start a phase 1 clinical trial to test a novel HIV vaccine candidate, BG505 SOSIP.664 gp140.

The study dubbed the International AIDS Vaccine Initiative W001 (IAVI W001) is aimed at assessing the safety of the candidate and to determine if vaccination induces the human immune system to produce proteins known as neutralizing antibodies (NAbs).

Subscribe to KAVI